99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS

• DOI: 10.1097/mnm.0b013e3282f5e5df
• Publication Date: 2008-04-30T07:10:36Z
• Authors: Luca Giovanella; Monica Taborelli; Luca Ceriani; Emanuele Zucca; Franco Cavalli; Angelika Bischof ...
• Keywords: Male; Technetium Tc 99m Sestamibi; Paraproteinemias; Reproducibility of Results; Sensitivity and Specificity; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Bone Marrow; Karyotyping; Humans; Female; Radiopharmaceuticals; Multiple Myeloma; Radionuclide Imaging

The first pathogenetic step in multiple myeloma is the emergence of a limited number clonal plasma cells, clinically known as monoclonal gammopathy undetermined significance (MGUS). Patients with MGUS do not have symptoms or end-organ damage but they 1% annual risk progression to related malignant disorders. With myeloma, complex genetic events occur neoplastic cell. Karyotyping and fluorescence in-situ hybridization (FISH) were shown be prognostic value patients myeloma. Tc-sestamibi imaging reflects disease activity bone marrow very high sensitivity specificity predicting evolution. This study was undertaken evaluate role cytogenetic analysis prognosis prediction myeloma.We enrolled 30 consecutive confirmed diagnosis MGUS. Bone biopsy biochemical staging according International Staging System (ISS) performed all cases. Karyotype FISH 11 12 17 18 having adequate metaphases.The karyotype abnormal four six Abnormalities chromosome 13 present one case cases whereas involvement immunoglobulin observed An panel found nine patients. All showed normal MIBI scan (score 0). Among only three, ISS stage I, while positive obtained others range, 1-7). uptake strongly cell infiltration abnormalities. Particularly, score above 5 identified poor encompassing III three seven II On other hand I less than good prognosis.Both add no relevant information Additionally, may useful guide order obtain samples for analysis.